Jenkem Technology Co., Ltd. Class ASSE: 688356

Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis

· Issued by Jenkem Technology Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis